Ask about this productRelated genes to: TRIM22 antibody
- Gene:
- TRIM22 NIH gene
- Name:
- tripartite motif containing 22
- Previous symbol:
- -
- Synonyms:
- STAF50, GPSTAF50, RNF94
- Chromosome:
- 11p15.4
- Locus Type:
- gene with protein product
- Date approved:
- 2001-08-10
- Date modifiied:
- 2016-10-05
Related products to: TRIM22 antibody
Related articles to: TRIM22 antibody
- Glioblastoma (GBM) is one of the most aggressive brain tumors with a poor prognosis despite current treatment modalities. This study aimed to identify genes whose high expression is paradoxically associated with both poor survival and enhanced immune activity, as potential targets for combination chemotherapeutic and immunotherapeutic strategies. - Source: PubMed
Publication date: 2026/04/27
Han Myung-HoonNoh Yung-KyunKim HyunkeeKim Kyu ShikKim Dong-HoonJung Un SukLee Kyung SukKwon Mi JungChae Seoung WanMin Kyueng-Whan - Acquired resistance limits the therapeutic efficacy of KRAS-MAPK inhibitors in pancreatic ductal adenocarcinoma (PDAC). As transcriptional plasticity and epithelial-to-mesenchymal transition (EMT) have been implicated in resistance, we sought to study the molecular mechanisms driving these changes to uncover actionable vulnerabilities. Sustained KRAS-MAPK inhibition induced interferon and NF-κB signaling and promoted cell state change mimicking an EMT state associated with drug resistance. Network analysis identified the interferon-inducible E3 ubiquitin ligase TRIM22 as a central regulator of this response. Mechanistically, TRIM22 promoted proteasomal degradation of IκBα, resulting in sustained NF-κB and EMT program activation that coincided with a basal-like transcriptional cell state. TRIM22 expression was driven by IRF1 and IRF9 following relief of ERK-mediated transcriptional repression during pathway inhibition. EMT induction was accompanied by marked upregulation of TROP2 (TACSTD2), an NF-κB target gene enriched in basal-like PDAC cell states. Combining TROP2-directed antibody-drug conjugate sacituzumab govitecan with KRAS or ERK inhibitors significantly suppressed PDAC tumor growth in xenograft models. Overall, prolonged KRAS-MAPK inhibition activates an interferon-TRIM22-NF-κB axis that drives EMT and therapeutic resistance in PDAC, while revealing TROP2 as a clinically actionable vulnerability to overcome acquired resistance. - Source: PubMed
Publication date: 2026/04/20
Bulle AshenafiChen YaliLi HuapingChen Timothy Hung-PoKhawar Iftikhar AliLi LinWang YuLiu PengSomani Vikas KumarKurupi RichardGeng YutongPereye Ofejiro BlessingBansod SapanaLe Son BRuzinova Marianna BTran David DLim Kian-Huat - Liver cirrhosis(LC) represents the end stage of chronic liver disease, yet reliable molecular markers remain limited. This study aimed to uncover potential diagnostic biomarkers and therapeutic targets for LC. - Source: PubMed
Publication date: 2026/03/14
Zhang KangChen TingJia ZhangyuZhao JunxiaHuang Na - - Source: PubMed
Publication date: 2026/02/28
Liu JinghongZhang JianboChen QunxiangQing WeijiaPeng YongchunHe ZhijingZhou XiPi HuifengLi BoLin QingyunLiu JunxinZhang FanZhang ShengFan Tengfei - Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus and a major cause of renal dysfunction, while reliable non-invasive biomarkers remain limited. Transcriptomic data from three LN cohorts were analyzed to identify differentially expressed genes (DEGs). Immune-associated DEGs were selected using WGCNA and prioritized via multiple machine learning algorithms. Diagnostic performance was evaluated with ROC curves and nomogram modeling, accompanied by functional enrichment and immune infiltration analyses. Independent validation was performed by qRT-PCR in peripheral blood samples from 13 LN patients and 10 healthy controls. A total of 320 DEGs were identified, including 53 linked to immune processes. In the transcriptomic datasets, four candidate hub genes (,,,) were initially identified. Furthermore, immune infiltration analysis suggested gene-specific immune interaction patterns, particularly associating with CD4⁺ T-cell–related signatures. qRT-PCR confirmed upregulation of and , while and showed no significant elevation. Accordingly, a refined two-gene signature was constructed, showing consistent discriminatory trends in the training dataset and the clinical validation cohort (AUCs > 0.9). and were consistently upregulated in the peripheral blood of patients with lupus nephritis and may represent potential immune-related biomarkers. - Source: PubMed
Publication date: 2026/02/20
Deng JiayiZhang ZimiaoLai YueyuanChen JinpengMa XiaomeiGao ZhenkaiLin ChaoLi XiaohongWu WeihaoChen CongjieShangguan XiaohuiHuang YanhongQiu HaoranQiu XiaomingChen Longtian